Human Model · HM(t) at day 111

State-timeSynthetic demo data⟨ I, S_t, H_0:t, E_t, Θ_t, T, U_t ⟩ — belief, not fact; uncertainty shown, not hiddenSteering view

Localization — where is this individual biologically now?

Belief state b_t per dimension: value ± sd from within-person noise plus the observation model's semantic distance. Trajectory features (velocity, autocorrelation, recovery time) are state variables.

Dimension	b_t	dS/dt	autocorr	recovery	observation model
Therapy response	61 ± 8.8	-0.29/d	0.65	18 d	Imaging + tumour markers, interpolated · proxy · last read ≤ 14 d
Gastrointestinal function	18 ± 4.6	-0.1/d	0.23	1 d	Daily GI check-in · direct · today
Treatment toxicity	21 ± 7.7	+0.2/d	0.63	1 d	Labs, interpolated between draws · proxy · last draw ≤ 7 d
Inflammatory activity	23 ± 10.9	+0.1/d	-0.01	10 d	CRP/ferritin + immune signature · inferred · weeks
Immune / metabolic	61 ± 11.1	-0.19/d	0.13	5 d	Metabolic panel + wearable · inferred · weeks
Nutritional sufficiency	65 ± 8	+0.1/d	-0.03	2 d	Weight, albumin, food log · proxy · days
Adherence	94 ± 4.4	+0.24/d	0.56	1 d	Dose + to-do completion · direct · today
Function / quality of life	66 ± 4.8	-0.04/d	0.21	2 d	PRO items · direct · today
Glycaemic control	122 ± 8	0/d	0	—	CGM daily mean · direct · today

High autocorrelation and slow recovery are early-warning signatures of a critical transition (Scheffer et al.), independent of the level.

Provenance — how did they arrive here?

The path H_0:t: baseline constraints, divergence, perturbations, actions and responses in order.

day 0baselineBaseline S13: EC-01 phenotype; Poor metabolizer; butyrate 29
day 8perturbationPoor-sleep week (-3)
day 50perturbationLow-HRV stretch (-2.7)
day 74perturbationDietary drift (-2.6)

Now: in the restoration basin, heading towards restoration.

Mechanism — which theories best explain the trajectory?

Versioned competing theories with supporting (E+), contradicting (E−) and missing-but-discriminative (E?) evidence. The contradiction engine lists what should NOT happen under each theory and whether it did.

T2 v2leading

confidence 51%

Bile-acid diarrhoea on a low-butyrate ecology: reduced SCFA production leaves bile acids unconjugated after fat-rich meals; GI burden tracks fat intake with a one-day lag.

E+

Butyrate capacity 29/100
DeepGene: 4 keystone butyrate producers absent
DeepGene: H2S above band
Fat load → GI +3.9 next day
Diversity 2.3

E−

E? · would discriminate

Faecal bile acids
7α-hydroxy-4-cholesten-3-one (C4)
Rechallenge: 3 high-fat days under observation

Forbidden under this theory

✓ holdsGI should not rise on low-fat days (fat effect 3.9 over 37 low-fat days)

v1 baseline: microbiome → v2 dietary attribution

T1 v1competing

confidence 36%

Mucosal barrier loss: drug-induced epithelial injury amplified by a FUT2-dependent glycan deficit; histamine and inflammatory load add on top.

E+

FUT2 non-secretor genotype (barrier glycan deficit)
DeepGene: Escherichia coli above range (LPS / zonulin)
DeepGene: tissue recycling 44

E−

E? · would discriminate

Faecal calprotectin (would separate barrier from motility)
Serum DAO / histamine
Zonulin

Forbidden under this theory

✓ holdsGI should not improve while histamine intake stays high (GI velocity -0.18/day)

✓ holdsLow-residue meals should reduce GI within a week (not tested)

v1 baseline: genotype + phenotype

T3 v1falsified

confidence 12%

Drug-exposure toxicity: pharmacokinetic over-exposure drives GI and systemic toxicity together; dietary and microbial factors are secondary.

E+

Poor metabolizer: exposure above modelled range
GI autocorrelation 0.66 (slow recovery)

E−

Toxicity within range

E? · would discriminate

Trough drug level
Dose-timing rechallenge (evening vs morning)

Forbidden under this theory

✗ violatedGI should not move with diet if exposure is the driver (4 dietary detractors with ≥ 80% confidence)

v1 baseline: pharmacogenomics

T4 v1competing

confidence 1%

Behavioural spiral: symptomatic days cut adherence and sleep, which raise GI and stress, which cut adherence further; the biology is a follower, not the driver.

E+

E−

Adherence intact
Sleep and stress stable

E? · would discriminate

Dose-taking timestamps vs symptom timestamps
Sleep-window rechallenge

Forbidden under this theory

✓ holdsGI should not worsen on days with full adherence and good sleep (insufficient paired days)

v1 from tracker trends

Forecast — which futures are likely under alternative actions?

30-day rollout of GI burden under the baseline model T and under each safe candidate action (effect ramps over onset). Dashed = prediction, never fact.

No action

GI 18 → 19

Intervention as measurement

Each past action as a measurement of this patient's transition dynamics: predicted ΔGI vs observed, prediction error ε_t, and the within-patient evidence patterns → individualized response confidence (observational, kept separate from randomized evidence).

No action started yet.

Decision — the Restore controller

Safe set computed first, then A* = argmax E[HealthGain + λ₁·InformationGain + λ₂·ConfidenceGain − λ₃·Risk − λ₄·Burden − λ₅·Cost]. λ₁ = 0.3 (a theory leads), λ₃ = 1 (stable enough). Execution stays with the clinician or the informed patient (EU MDR Class I).

Class	Action	Health	Info	Conf.	Risk	Burden	Cost	Utility
Observe	Continue passive collection, no perturbation A clean transition can be observed only without a new perturbation.	0	0.15	0.05	0	0.05	0	0.03
Measure	Faecal bile acids Discriminates T2 from its competitors (E?).	0	0.45	0.2	0.02	0.25	0.2	0.01
Maintain	Hold current regimen and content Protects nothing while the state deteriorates.	0.05	0.05	0.05	0.05	0.05	0	0
Test	7α-hydroxy-4-cholesten-3-one (C4) Discriminates T2 from its competitors (E?).	0	0.45	0.2	0.02	0.25	0.5	-0.05

Excluded from the safe set

HY-01 Not indicated for the current state.
DT-01 Not indicated for the current state.
GI-04 Not indicated for the current state.
AD-05 Not indicated for the current state.
ME-01 Not indicated for the current state.
BR-03 Not indicated for the current state.
NP-02 Not indicated for the current state.
SC-12 Not indicated for the current state.
CR-01 Not indicated for the current state.

Evidence weights · w = Authority × Relevance × Persistence

Biological identity Poor metabolizer; FUT2, IL6, CYP2D6, MTHFR
Germline panel, baseline
0.86 (0.95·0.9·1)
High-authority clinical Toxicity 21, response 61
Labs / imaging, ≤ 14 d
0.77 (0.9·1·0.85)
Intervention response 0 within-patient responses recorded
ΔS after each action, accumulating
0.68 (0.75·1·0.9)
Deep biological state DeepGene retest day 90: damage 64/100, Shannon 2.48, butyrate 541 CPM, 4 opportunists above, 4 keystone absent
Synthetic DeepGene metagenomics + host DNA, sample 940581-R (compositional proxy)
0.56 (0.7·1·0.795)
Dynamic state GI 18, sleep 7.4 h, HRV 64, glucose 122
Companion + wearable, today
0.18 (0.6·1·0.3)
Exposure context Keep meals regular; three to four moderate portions spaced through the day; dosing per protocol; adherence 94%
Food log + dose log, event-level
0.1 (0.55·0.9·0.2)

LLIFE OS insight · the five questions, in prose

grounded · add an LLM key for prose

P-02420 is on day 111 of META-24 (EC-01, baseline S13): response improving, tolerance deteriorating, GI favorable. Over 14 days response moved +5 and GI -2; discontinuation risk is 13%. The state is in the restoration basin, heading towards restoration.

Biology sets the gain: FUT2 non-secretor, IL6 high-expression variant, Poor metabolizer, Low butyrate capacity, Low microbial diversity; butyrate capacity 29/100, diversity 2.3. Pushing it down: Escherichia coli 21.984% (LPS load) (-34.8), Low butyrate capacity (-27.3), 4 keystone species absent (-20.4). From the daily log: fat +3.9 GI next day, alcohol +3.9 GI next day, ultra-processed +2.8 GI next day, protein -2.7 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.